Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
Merus N.V. (MRUS) CEO to participate in fireside chat at Leerink Partners Global Biopharma Conference. The company is a clinical-stage oncology firm focusing on innovative multispecific antibodies.
03/04/2024 - 08:00 AM
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics® ), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 12:00 p.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics® . Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website , X and LinkedIn .
Multiclonics® , Biclonics® and Triclonics® are registered trademarks of Merus N.V.
When will Bill Lundberg, M.D., CEO of Merus N.V. (MRUS), participate in a fireside chat?
Bill Lundberg, M.D., CEO of Merus N.V., will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 12:00 p.m. ET.
What type of antibodies is Merus N.V. (MRUS) developing?
Merus N.V. is developing innovative, full-length multispecific antibodies known as Biclonics® and Triclonics®.
Where can investors watch the webcast of the presentation by Merus N.V. (MRUS) CEO?
Investors can watch the webcast of the presentation by Merus N.V. CEO on the Investors page of the Company's website.
MRUS Rankings
#2121 Ranked by Stock Gains
MRUS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Netherlands
City
Utrecht
About MRUS
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
